Nycomed

Nycomed was a Swiss pharmaceutical company that had been acquired by a major European private equity firm and had expanded significantly through inorganic growth. The E3 Life team joined the Commercial Operations team in 2011 to pursue growth opportunities in emerging markets.

Nycomed expanded its commercial footprint in Emerging Markets through numerous targeted licensing deals and a transformative acquisition in China, which established the foundation for further organic growth.

The expanded footprint supported by the E3 Life team was a key driver for Nycomed’s acquisition by a major strategic acquirer for an attractive investment return.